See It In Action
Big pharma trusts Kazakhstan.
With over 250 trials conducted to date, Kazakhstan has a decade-long track record with the world's leading pharmaceutical companies.
A clinical trials platform in Kazakhstan, partnering with global biopharma to accelerate clinical programs. Built by biotech operators and investors to solve the cost and timeline crisis killing early-stage programs.
Capital concentration and escalating investor expectations prevent startups from funding the clinical trials needed to reach approval, regardless of scientific merit.
82% of biotech capital is controlled by just 11 mega-funds. The median cost to reach FDA approval is $2 billion, yet most startups will never raise more than $30M. 86% of all capital flows to late-stage trials, leaving Preclinical and Phase I programs starved. The result: more than 90% of startups never raise enough to complete a clinical trial. Too many breakthrough therapies die not in the lab, but on a spreadsheet.
A clinical trials platform built in Kazakhstan, partnering with global biopharma to accelerate clinical programs. Built by biotech operators and investors, Vantage solves the cost and timeline crisis killing early-stage programs while making the financial math work for the first time.
Kazakhstan's clinical trial legislation and protocols are modeled directly on FDA standards. Data accepted simultaneously by EMA, NMPA, and MHRA. One trial, global regulatory coverage.
Streamlined approvals, minimal bureaucracy, and accelerated patient recruitment enabled by government-backed infrastructure and a rapidly maturing clinical ecosystem.
Government-owned hospitals and structurally lower healthcare costs make early-phase trials financially viable across all indications and phases of development.
The government owns and operates the healthcare system and is actively building a national biopharma ecosystem. Institutional support unavailable in most trial jurisdictions.
With over 250 trials conducted to date, Kazakhstan has a decade-long track record with the world's leading pharmaceutical companies.
Tigermed serves as Vantage's global CRO partner, reinforcing executional rigor, regulatory compliance, and multinational trial capability, while Vantage remains the lead platform for infrastructure access, government integration, and trial delivery in Kazakhstan.
Tigermed brings world-class trial execution, monitoring, and regulatory expertise across 37 countries. Together, we deliver a fully integrated path from protocol to approval.
Together, we conduct low-cost, expedited clinical trials per our exclusive relationship with the Kazakhstan government and unequivocal access to their resources, facilitating R&D and clinical advancement currently unavailable elsewhere on similar terms while operating in accordance with the FDA standard.
Infrastructure, Government Integration, Sites
Execution, Monitoring, SOPs, Regulatory Compliance
From protocol to approval. A fully integrated path to running your clinical trial in Kazakhstan.
Share your clinical trial protocol and therapeutic objectives with the Vantage team.
Vantage and Tigermed assess feasibility, regulatory pathway, and cost structure.
Costs, timelines, site recommendations, and regulatory pathway, all detailed.
Your FDA-aligned trial runs on Vantage infrastructure with Tigermed's execution platform.
The FDA does not evaluate clinical data by country of origin.
The FDA reviews integrated datasets submitted in an NDA or BLA. It evaluates them against GCP compliance, data integrity, and inspection access — all conditions Kazakhstan satisfies under its existing regulatory framework. Major pharmaceutical sponsors including Roche, Pfizer, Sanofi, Eli Lilly, and Johnson & Johnson have already conducted registered trials there. Multiple FDA-approved drugs had pivotal or supportive trial sites in Kazakhstan, including Vonjo, Keytruda, Rinvoq, Alecensa, and Tecentriq. The infrastructure is validated. The question is one of execution quality, not geography. That is where Vantage and Tigermed deliver.
Read the Full AnalysisShare your clinical trial protocol and therapeutic objectives with the Vantage team. We will evaluate feasibility, regulatory pathway, and cost structure, and return a full proposal with costs, timelines, and site recommendations.